Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Clinical trial NCT04751383 · TERMINATED

Trial details

NCT number: NCT04751383
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

High Risk Neuroblastoma Recurrent Neuroblastoma Recurrent Osteosarcoma Refractory Neuroblastoma Resectable Osteosarcoma

Start date: 2021-08-31
Primary completion: 2024-09-30
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.